The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Akero Therapeutics Inc COM 00973Y108   10,154,300 365,000 SH   SOLE   365,000 0 0
Allogene Therapeutics Inc COM 019770106   7,344,826 3,448,275 SH   SOLE   3,448,275 0 0
Alumis Inc COM 022307102   33,032,986 4,202,670 SH   SOLE   4,202,670 0 0
Bicara Therapeutics Inc COM 055477103   16,549,000 950,000 SH   SOLE   950,000 0 0
Casi Pharmaceuticals Inc ORD SHS G1933S101   3,762,154 1,329,383 SH   SOLE   1,329,383 0 0
Centessa Pharmaceuticals Inc SPONSORED ADS 152309100   20,994,098 1,253,379 SH   SOLE   1,253,379 0 0
CG Oncology, Inc. COM 156944100   63,711,874 2,221,474 SH   SOLE   2,221,474 0 0
Corvus Pharmaceuticals Inc COM 221015100   8,459,597 1,581,233 SH   SOLE   1,581,233 0 0
Cullinan Therapeutics Inc COM 230031106   7,728,916 634,558 SH   SOLE   634,558 0 0
Edgewise Therapeutics Inc COM 28036F105   15,619,500 585,000 SH   SOLE   585,000 0 0
Kymera Therapeutics Inc COM 501575104   5,886,936 146,332 SH   SOLE   146,332 0 0
Rapt Therapeutics Inc COM 75382E109   19,750,000 12,500,000 SH   SOLE   12,500,000 0 0
Structure Therapeutics Inc SPONSORED ADS 86366E106   11,390,400 420,000 SH   SOLE   420,000 0 0
Viridian Therapeutics, Inc COM 92790C104   37,842 1,974 SH   SOLE   1,974 0 0